NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









3T Biosciences

3T Biosciences

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://3tbiosciences.com/

Last Round

Series A

Aug 25, 2022

Total Funding Raised

$52M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

3T Biosciences is a biotechnology company that develops next-generation T-cell receptor (TCR)-based immunotherapies for solid tumors and immune-mediated diseases using a proprietary target discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

immunotherapyT-cell receptorTCRdrug discoverytarget identificationprecision medicinebiotech platformoncologyAI drug discoveryTCR-based therapyin silico discoveryoff-target toxicitybiopharma partnershipcomputational biologydrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

3T Biosciences Comparables

Compare 3T Biosciences with similar companies based on industry and business-model similarity.

3T Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ImmunoScape
86%
BlueSphere Bio
84%
Enara Bio
82%

3T Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AAug 25, 2022
SeedOct 5, 2017

Key People

Founding team and executive leadership

Marvin Gee

Chief Research Officer, Co-Founder

Founding Team

John Connolly

Interim CEO

Executive Team

Stefan J. Scherer

Chief Executive Officer

Executive Team

3T Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 58, 232% of headcount.

  • Jun 18, 2026

    Monthly visitors increased 60% MoM.

3T Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

3T Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about 3T Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range25
Year Founded2017
Last FundingAug 25, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.